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Introduction
There has been a worldwide increase in autism cases in the past 
few decades, but the cause of it is unclear.  It has been suggested 
that vaccines may be contributing to the rise in autism rates. 
One claim is that the MMR vaccine can cause intestinal inflam-
mation that may lead non-permeable peptides to be transferred 
to the brain where it will affect neurodevelopment.  This may 
lead to autism with symptoms of developmental regression 
and gastrointestinal problems. Another major hypothesis that 
has received much attention is that a mercury-containing com-
pound, thimerosal, found in many vaccines, can have toxic effects 
on the central nervous system.  By retrieving studies from data-
bases such as Ebsco, Proquest, and Pubmed found in the Touro 
College Library, this review investigates if there is any truth to 
these claims.  No evidence of a direct link between vaccines and 
an increase in autism cases have been found. 
Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental dis-
order that impairs a child’s ability to interact and communicate 
with others.  It is commonly associated with certain behaviors 
such as difficulty making conversation, delayed language acqui-
sition, and poor motor skills.   Autism seems to originate from 
very early brain development.  The most obvious symptoms of 
the disorder, however, usually begin to show between the ages 
of 2 and 3. (Autism Speaks, 2016)  Autism diagnoses have great-
ly increased in the past few decades.  According to statistics 
from the U.S. Centers for Disease Control and Prevention, the 
prevalence of autism in 1000 children was approximately 6.7 in 
the year 2000 and 14.7 in 2010, a significant increase.  (Data & 
Statistics, 2015). The cause for this dramatic increase is unknown 
and has been the subject of much investigation.  It is believed 
that genes play a role in an increasing risk for autism (Mascarelli, 
2010). However, environmental factors play a part in most cases 
of autism too.  There has been a growing concern of a possible 
link between vaccines and autism.  Two separate theories have 
been proposed over the years.  One is that the Measles-Mumps-
Rubella (MMR) vaccine causes autism.  The other is that thimer-
osal, a mercury containing preservative found in many vaccines 
can lead to damage in the brain.  Researchers have sought to 
discover if there is any truth to these claims. 
Methods
Information and research was obtained through databases such 
as Ebsco, Proquest, and Pubmed.  Access was provided by the 
Touro College Library.  Google Scholar was also used to find 
research articles. Keywords like vaccines, autism, and thimerosal 
were used to search for relevant material.  In addition, refer-
ences in these articles were retrieved and used as additional 
sources for further research.
Discussion
MMR Vaccine
In 1968 a link was suggested between the Mumps, Measles, and 
Rubella (MMR) vaccine and the onset of ASD.   Unusual bowel 
symptoms were described among 12 children who showed de-
velopmental regression like losing acquired skills despite previ-
ous normal progress.  Eight out of the twelve children who had 
gastrointestinal signs had reported their first symptoms of au-
tism within a month of receiving the MMR immunization.  It was 
concluded that the MMR vaccine caused intestinal inflammation 
allowing usually non-permeable peptides to be translocated to 
the bloodstream and ultimately to the brain, where they affect-
ed development. (Wakefield, et al. 1998) Although the sample 
was small with only a dozen children and the results were never 
replicated, the study received lots of attention from the pub-
lic, and served as the foundation for much controversy in the 
years to come.  Parent’s anecdotes of their own personal ex-
periences were enough for many to keep this alive.  As a result, 
many refused to vaccinate their children worrying about their 
safety, and outbreaks of vaccine preventable diseases began re-
appearing in certain areas.  The MMR-autism controversy was 
responsible for a significant decrease in immunizations following 
that year.  The MMR immunization rates in the United Kingdom 
dropped from 90% in 1988, when they were first introduced, 
to 80% in 2004, after the article had been read by the public. 
(Kolodziejski, 2014)
Possible Developmental Regression and 
Gastrointestinal Symptoms Associated with MMR
Whether MMR is really associated with autism has been under 
constant debate.  There have been many studies done to see if 
the link exists.  Fombonne and Chakrabarti (2001) tested out 
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the hypothesis that a form of autism existed involving devel-
opmental regression and gastrointestinal symptoms caused by 
the MMR vaccine.  It was proposed that if one or more of the 
following predictions were proved by the data collected, the hy-
pothesis could be validated.  The first prediction was that child-
hood disintegrative disorder (CDD) had become more com-
mon.  Another is that the average age of first parental concern 
in autistic children in those who received the MMR vaccine is 
closer to the mean age of immunization than in those who were 
not vaccinated with MMR. The third prediction was that devel-
opmental regression in those who are vaccinated with MMR 
had become more frequent.  If the age of onset of autism with 
regression is closer to MMR-vaccination as opposed to those 
who did have autism without regression, it could also prove 
that MMR could have caused autism.  Another prediction is that 
those with regressive autism have different symptoms.  Finally, 
those with regressive autism would have gastrointestinal signs 
and/or inflammatory bowel disorder. 
Three samples, 1 epidemiological (n=96) and 2 clinical sam-
ples, a pre-MMR (n=68) and a post-MMR (n=98) were used 
to gather information.  In order to assess age of first onset of 
autistic signs, the parents were asked how old their child was 
when they first became concerned with his/her development. 
Regression was noted when a loss of skill, such as language 
was confirmed based on certain criteria.  Assessment of bowel 
symptoms was done by retrieving data from both the parents 
and pediatrician.  
The first prediction of childhood disintegrative disorder (CDD) 
increasing was not supported by the data as only one boy met 
the criterion for CDD, which seems likely to have originated 
from brain pathology before the MMR immunization was even 
given.  In this epidemiological sample where nearly all the chil-
dren were vaccinated, it can be assumed that CDD is not in-
creased with vaccine exposure.  Second, there was no difference 
in age of first parental concern in two of the samples exposed to 
MMR (19.3 and 19.2) compared to the pre-MMR clinical sample 
(19.5).  Third, the rate of regression for the post-MMR sample 
(15.6%) was lower than the rate in the pre-MMR sample (18.4%). 
This rules out MMR-induced regressive autism as a cause for 
the dramatic increase in autism cases.  In the epidemiologic 
sample, 18.8% had gastrointestinal symptoms.  Constipation was 
the most common symptom (9.4%), and no inflammatory bowel 
disorder was reported. Only 2.1% of the sample experienced 
both developmental regression and gastrointestinal symptoms, 
a rate which shows no association between the two.  None of 
the 6 predictions were supported in this study, and no evidence 
was found to show a distinct syndrome of MMR-induced autism. 
(Fombonne E, Chakrabarti S, 2001). 
Measles Virus RNA in Patients with Autism
There are studies that have reported Measles Virus (MV) RNA 
in bowel biopsies in autistic children, showing a possible link 
between intestinal inflammation and the measles virus.  A study 
done by Kawashima et al (2000), examined children with gastro-
intestinal problems to see if they have the measles virus and if 
they did, if it derived from wild strains or vaccine strains. Eight 
of the patients had Crohn’s disease, 3 had ulcerative colitis, and 
9 had autistic enterocolitis.  One of the patients with Crohn’s 
disease, 1 with ulcerative colitis, and 3 of 9 with autism were 
positive for the virus, while the controls were all negative.  The 
measles virus found in the patient with Crohn’s disease proved 
to have characteristics of wild-strain virus, while the one with 
ulcerative colitis and in the autistic patients had vaccine strains.
A study including 125 autistic children and 92 control children. 
MMR antibodies were first measured by ELISA in sera of 24 
randomly selected autistic children, 16 normal children, and 14 
children with other developmental problems.   Autistic children 
had a higher number of MMR antibodies compared to the other 
children.  Soon after all of the 217 children were checked for 
MMR antibodies by immunoblotting assay for serum screening. 
They found that 75 (n=125) autistic children’s sera were positive 
for an unusual MMR antibody, whereas none of the control sera 
had the antibody. A protein band was detected in the antibody 
which was immunopositive for measles HA protein but not for 
measles nucleoprotein and rubella or mumps viral proteins.  The 
results showed that autistic sera detected measles HA protein 
in the MMR antibody.  It is suggested that an inappropriate anti-
body response to MMR might be related to the development of 
autism.  (Singh, et al, 2002)
However, despite those few studies, many studies have been 
done that disprove the link between autism and MMR including 
a few that failed to detect MV-RNA in cases of autism.  A case 
control study tested for the presence of measles virus (MV) 
RNA in bowel tissue in children with ASD. The purpose was to 
see if those with GI disturbances and autism are more likely to 
have MV RNA in their bowel tissue than those with GI symp-
toms but no autism.  This can determine if MMR is linked to this 
type of autism.  The ileal and cecal tissues of 25 children with GI 
disturbances and autism and 13 children with GI disturbances 
but no autism were analyzed for MV RNA in 3 different labora-
tories.  The timing of the autistic and gastrointestinal symptoms 
in respect to MMR immunization was also documented.  The 
results showed no difference in MV RNA findings in the case 
group and the control group.  The timing of the vaccine in re-
gards to the GI symptoms and autism onset were inconsistent 
with the theory that MMR triggers either the GI symptoms or 
autism.  (Hornig, et al, 2008) 
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A 14 year prospective study reviewed the number of vaccines 
that were given from the time The National Board of Health 
and National Public Health Institute launched their MMR vac-
cination program in 1982 till the year 1996.  3 million vaccines 
were given during that period of time and 31 cases of gastro-
intestinal symptoms were reported after vaccination, ranging 
from 20 hours to 15 days.   Fifty five percent (n=17) had symp-
toms of diarrhea and vomiting, 23% (n=7) had gingivostomatitis, 
16% (n=5) had vomiting only, and (n=2) had abdominal pains. 
The symptoms usually lasted about a week.  None of the chil-
dren developed autism.  In this study, no association was found 
between MMR and pervasive developmental disorder or inflam-
matory bowel disease.  (Peltola et al, 1998)
Epidemiological Studies
Numerous epidemiologic studies have been done to see if there 
is an association between MMR and autism.  Taylor, et al (1999) 
did a chart review of cases of autism diagnosed in a region in 
England, in children born between 1979-1992.  They identified 
498 cases of ASDs in the population, of which only 293 could 
be confirmed according to ICD-10 criteria. They analyzed the 
data in different ways to test if autism was related to the MMR 
vaccination. Data they collected included the age at which the 
children were diagnosed, the age of first parental concern, and 
age when regression became obvious.  The trend of autism 
was examined to see whether or not there had been a sudden 
step-up in autism diagnoses in children who received the MMR 
vaccine after it was introduced in England in 1988.  They found 
that the prevalence rates of autism began an exponential rise 
starting with children born a couple of years before the intro-
duction of the MMR vaccine, and that there had been no sudden 
step-up after 1988.  They concluded that this refuted a temporal 
relationship. 
A study done in California collected data regarding MMR cov-
erage rates and age at the time of immunization for children 
born between the years 1980-1994 from school immunization 
records in California Kindergartens.  The number of cases of 
autism diagnosed during those years were retrieved from the 
California Department of Developmental Services where they 
were enrolled.   The results did not show a correlation between 
rates of autism and number of immunizations given.  As can 
be seen by Figure 1, autism cases increased from 44 cases per 
100,000 live births in the 1980 cohort to 208 cases per 100,000 
live birth in the 1994 cohort, a 393% increase.  In contrast, MMR 
immunization rates by the age of 24 months increased from 
72% to 82%, only a 10% increase.  Since the rate of increasing 
autism cases does not compare with the only small rise in MMR 
coverage, a correlation was not observed between the two. 
(Dales, et al, 2001)
A population study was done in Japan by Honda, et al (2005).  It 
examined incidence of ASD in children born from 1988-1996. 
Japan’s MMR immunization program was launched in 1989 but 
ended in 1993, due to suspected side effects of the mumps vac-
cine.  This allowed for an opportunity to research the effect 
of removing the MMR vaccine which was believed to cause a 
rise in autism.  If it was really the cause of the increased autism 
caseloads when it was introduced, autism would drop after the 
risk factor (MMR vaccine) was withdrawn.  All children who had 
been diagnosed with ASD were selected from a patient list of 
the YRC Developmental Psychiatry Unit, which offers diagnostic 
and intervention services to all those with ASD.  The annual 
trends for both typical autism and all other categories of ASD 
were examined.  According to the statistics, MMR vaccination 
rates were 69.8%, 42.9%, 33.6%, 24.0%, and 1.8% respectively 
in the years 1989-1993.  As can be seen by this data, the rate 
decreased significantly during these years, with only a bare mini-
mum of 1.8% of children vaccinated with MMR in the year 1993. 
The annual trends of ASD were compiled for the years 1988-
1996.  The ASD incidence rates ranged from 47.6 per 10000 in 
1988 to 117.2 per 10000 in those that were born in 1996.  The 
rate of autism incidences continued to rise even after the MMR 
vaccination program was terminated.  This provides evidence 
that it is highly unlikely that MMR is linked to greater autism 
incidences. (Table 1) (Honda, et al, 2005)
Percentage of Children Receiving Measles-Mumps-Rubella (MMR) 
Immunization in Second Year of Life and Caseload of Children With 
Autism, by Year of Birth, California, 1980-1994 (Dales, et al, 2001)
Figure 1
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Thimerosal
Since the 1930s, thimerosal, a mercury-containing preservative 
has been used in many biological and drug products, including 
multi-dose vaccines, to prevent bacterial and fungal contamination 
Thimerosal is not found in live vaccines, such as MMR because of 
the damaging interaction they can have with the active substance. 
Before 1991, diphtheria-tetanus-pertussis (DTaP) vaccination was 
the only common vaccine that contained thimerosal.  Recently 
though, more vaccines have been introduced that consist of thi-
merosal like Hepatitis B and HIB.  (Nelson, Bauman, 2003) Too 
much mercury can have toxic effects especially in little children, 
where the brain is still developing.  As can be seen by Table 2, 
the FDA estimated that 6-month old babies could have received 
doses of mercury as high as 187.5 µg in their vaccines and 2 year 
olds as much as 237.5 µg.  (Freed, et al, 2002)
Because of the increasing amount of this chemical that babies 
were being exposed to, there was a growing concern that the 
ethylmercury which is found in thimerosal can cause brain dam-
age and contribute to autism.  Fearing this, the FDA removed 
thimerosal from all vaccines in 1999 even though direct evi-
dence of harm was not found.  Since not much was not known 
about ethylmercury at that point in time, assumptions were 
made based on knowledge of methylmercury.  Methylmercury 
was known to have toxic effects and many assumed that 
ethylmercury has similar consequences. 
Since ethylmercury had not been exten-
sively studied, researchers began to ex-
periment with ethylmercury to see if it 
can really have those damaging effects in 
vaccines.  (Straton, 2001)
Research was done by analyzing the 
VAERS database, a database maintained by 
the CDC which holds a record of all ad-
verse reactions.  The VAERS database was 
used to compare the neurodevelopmental 
disorders that were found following the administration of thi-
merosal-containing DTaP vaccines in contrast to thimerosal-free 
DTaP vaccines. A close linear correlation was found between in-
creasing mercury due to thimerosal vaccines and an increase in 
the odds ratio of neurodevelopmental disorders.   According to 
the results in the baseline year of 1984, the odds ratio of autism 
increased by 0.029 per mg of mercury, personality disorders by 
0.012 per mg of mercury, and mental retardation by 0.048 per 
mg of mercury.  The total odds of developing autism increased in 
those immunized with thimerosal-containing vaccines vs those 
who received thimerosal-free vaccines.  This study showed that 
more research had to be done to see if there is indeed a cor-
relation between mercury levels and higher risks of autism and 
other developmental disorders.  (Geier et al, 2003)
A study done used hair and urine analysis to detect heavy metal 
exposure in those with autism compared to those who did not 
have autism.  It consisted of 25 autistic children and 25 con-
trols.  Metal testing was performed via ICP-MS spectroscopy 
utilizing cell technique to detect levels of different metals in the 
hair. The mean mercury level in the hair of autistic children was 
0.47±0.42 while the levels in the control children was a lower 
mean of 0.30±0.3.  A similar observation was found of the mer-
cury levels in the urine of autistic children compared to control 
children, with means of 2.48±2, and 1.10±0, respectively. These 
results seem to show an association between higher levels of 
mercury in those with autism.  Limitations in the amount of 
mercury they ingest seems to be important for the safety of 
these children.  However, a larger sample size should be studied 
on in order to validate these findings.   (Blaurock-Busch, 2011)
A study was done by Pichichero et al, (2002) to measure the 
concentration of mercury found in infants’ stool, blood, and 
urine after they received vaccines.  If high levels were found, it 
would show that thimerosal can be potentially harmful in vac-
cines.   In this experiment, 40 infants who were 6 months or 
younger received thimerosal containing vaccines while 21 con-
trols received thimerosal free vaccines.  Samples of the infants’ 
stool, blood, and urine were obtained 3-28 days after and were 
Table 2
Table 1
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tested for mercury levels.  Blood samples contained low levels 
of mercury with a range of 4.50-20.55 nmol/L.  Fourteen out of 
15 controls did not have quantifiable levels of mercury.  Those 
with the highest levels of mercury were infants who were mea-
sured soon after they were vaccinated.  There was no mercury 
found in urine samples, besides for one of the 2-month olds 
and three of the 6-month olds who had received thimerosal 
in their vaccines.  The highest amount of mercury in the urine 
was 6.45 nmol/L.  No mercury was found in any of the control 
infants.   Detectable amounts of mercury were found in stool 
samples in those who were exposed to thimerosal containing 
vaccines.  Those who did received thimerosal free vaccines were 
not measured for mercury levels in their stool. (Table 3)
To determine if dietary intake could contribute to mercury 
levels in the stool, samples were obtained from 9 infants who 
were age-matched to those who received thimerosal containing 
vaccines but were not exposed to thimerosal themselves.  The 
mean levels of mercury in these samples was 22 ng/g which 
was considerably lower than those exposed to thimerosal.  Out 
of all these samples, however, no concentration exceeded 29 
nmol/L which is known to be an accepted safe value.  The results 
did show an increased amount of mercury in those who were 
vaccinated compared to those who did not receive thimerosal, 
but the quantity was still below the harmful level.  Before the 
samples were measured, a prediction model was made of the 
expected measurements of mercury corresponding to the pos-
sible half-life days ranging from 1-45.  The best estimate of the 
half-life of ethylmercury would be the difference between the 
predicted value and the observed value.
The concentration of mercury in the blood not long after vac-
cination suggests that the half-life of ethylmercury is not nearly 
as long as the half-life of methylmercury.   As we can see from 
Figure 2, the estimated half-life for ethylmercury was 7 days. 
This contrasts with the half-life of around 40-50 days in meth-
ylmercury.  The long half-life of methylmercury can allow the 
organic-mercury to cross over the blood brain barrier where it 
can accumulate and get converted to inorganic mercury which 
can cause neurodevelopmental damage.  Ethylmercury, however, 
which is found in thimerosal is rapidly eliminated through the 
stool which prevents toxicity from accumulating that could be 
detrimental to parts of the body including the brain.  (Pichichero, 
et al, 2002)
Since creating controlled experiments is not possible in an ex-
isting vaccination program, determining if there is an association 
between thimerosal and autism is not so simple.  Several epi-
demiological studies have been done to see if there is a causal 
relationship between receiving thimerosal containing vaccines 
and an increase in autism cases.   A population cohort study of 
children in Denmark who were born in the years 1990-1996 
was done to compare children who received thimerosal in their 
vaccines and those who did not.  Doses that were adminis-
tered before 1992 were considered to be vaccines containing 
thimerosal and those doses given after 1992 were thimerosal 
free vaccines.  Information regarding vaccine administrations 
was obtained from the Danish Board of Health and data regard-
ing autism diagnoses was retrieved from the Danish Psychiatric 
Central Register.  Follow ups were done from one year of age 
till the year 2000 to see if there would be possible cases of au-
tism disorders in those children.  During these years, 440 cases 
of autism and 787 cases of other autistic-spectrum disorders 
were diagnosed among those children (table 4).  
Table 3
Figure 2
Table 4
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We can see from the results shown in table 4, that when com-
paring those who received at least one dose of thimerosal-con-
taining vaccine and those who only received thimerosal-free 
vaccinations there was a rate ratio of 0.85% for autism and 
1.12% for other autistic spectrum disorders. Also, there was 
no association between a higher dose of thimerosal-contain-
ing vaccine and a higher rate of autism disorders.  The increase 
in rate ratio per 25 ug of mercury was 0.98% in autism and 
1.03% in other autistic spectrum disorders.  In order to rule out 
the possibility that some thimerosal-containing vaccines were 
administered soon after 1992, the vaccinations between June 
and December of 1992 were omitted from the data and similar 
results were found.  This study showed no association between 
thimerosal intake and increased autism rates.  (Hviid, et al, 2003)
In the United Kingdom, the only thimerosal containing vaccines 
that have been administered in the past few decades is DTaP 
and DT.  The total amount of thimerosal per dose in these vac-
cines is 50 ug (25 ug of ethylmercury).  In the United Kingdom, 
the schedule for vaccination called for 3 doses by the age of 4 
months, totaling 150 ug of thimerosal at that age.  Data regarding 
date of birth and vaccination dates were obtained for 109,863 
children who were born from 1988 to 1997.  Some children 
were excluded from the study including those who had certain 
medical conditions before the age of 6 months and those who 
had received the Hep B or flu vaccination before 6 months of 
age.  Hg exposure was calculated based on the number of vac-
cine doses the children received.  A number of developmental 
disorders were investigated and the number of cases diagnosed, 
the mean age of diagnoses, and the percentage that was male 
was assessed.  When these children were linked to the dates of 
their vaccination and any of the neurodevelopmental disorders 
they had, no evidence of increasing neurodevelopmental disor-
der rate was found with an increasing dose of ethylmercury. 
The only disorder that showed a possible link to thimerosal was 
tics, which had a hazard rate of 1.50 in 4 months of age.  The rest 
of the disorders had a Hazard rate close to 1, showing no link to 
thimerosal.  (Andrews, et al, 2004) 
Another study was done in Sweden and Denmark to compare 
the prevalence of autism cases with the exposure of thimero-
sal-containing vaccines during the 1980s and 1990s.  Data re-
garding vaccine coverage and autism cases were collected in 
these countries.  The total amount of ethylmercury exposure 
was calculated by multiplying the amount of thimerosal in vac-
cines by the number of vaccines with thimerosal administered 
during that time period.  The rate of autism was calculated by di-
viding the total number of autism cases diagnosed in those years 
by the number of person-years accumulated during those years. 
As shown in figure 3a, the incidences of autism in Sweden began 
to rise in the year 1985 to a rate of around 6 per 100,000 
person-years and peaked in the year 1993 to a rate of 9.2 per 
100,000 person-years.  The coverage of thimerosal-containing 
vaccines, however, have remained steady over most of those 
years, decreasing over time and eventually being completely 
removed in 1993.  A similar explanation goes for Denmark, 
shown in figure 3b.  Thimerosal-containing vaccination coverage 
remained constant throughout the years 1981-1991 and ended 
in 1992, but autism rates continued to increase sharply in the 
years after that.  We can see from these studies that the rise of 
autism needs a better explanation than the exposure of thimer-
osal to children. 
Conclusion
From the studies that have been done so far, no evidence 
has been found to show a link between vaccines and autism. 
Increasing autism rates need to have another explanation.  It 
has been suggested that the broadening of the diagnosis, and the 
greater awareness of autism and other ASDs have contributed 
to more diagnoses of autism.  The claim that MMR is associated 
Figure 3a
Figure 3b 
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with a regressive form of autism has been proven to be highly 
unlikely. The fact that MMR vaccination withdrawal did not lead 
to a decrease in autism cases indicated that there is not any cor-
relation between the two. The concern that thimerosal-contain-
ing vaccines cause autism has also not been validated.  However, 
despite the shorter half-life and less damage that ethylmercury 
can have in comparison to other mercury compounds like 
methylmercury, the current literature does not rule out a role 
for thimerosal in neurodevelopmental damage other than au-
tism to children. Therefore, it is best that thimerosal continue 
to remain excluded from vaccines.
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